Companies › Boehringer Ingelheim
42 active drug programs in 173 registered trials: 71 Phase 1, 41 Phase 2, 35 Phase 3, 26 Phase 4; Oncology, Other, Gastroenterology, Respiratory; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Survodutide Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist | GLP1R, GCGR | Phase 3 | Type 2 Diabetes; Metabolic Dysfunction Associated Steatohepatitis; Metabolic Dysfunction Associated Steatohepatitis (MASH); Healthy … | Dec 2026 |
| Zongertinib HER2 inhibitor | ERBB2 | Phase 3 | Lung Cancer, Non-squamous, Non-small Cell; Non-small Cell Lung Cancer; Solid Tumours; Healthy … | Dec 2026 |
| Empagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 3 | Chronic Kidney Disease; Heart Failure; Healthy; Diabetes … | Dec 2026 |
| Vicadrostat | – | Phase 3 | Heart Failure; Diabetes Mellitus, Type 2; Healthy | Dec 2026 |
| Verducatib (BI 1291583) Lysophospholipase A1 (LYPLA1) inhibitor | LYPLA1 | Phase 3 | Bronchiectasis; Healthy | Dec 2026 |
| BI 690517 Finerenone-like non-steroidal mineralocorticoid receptor antagonist | NR3C4 | Phase 3 | Kidney Disease, Chronic | Dec 2026 |
| Obrixtamig DLL3-targeting antibody-drug conjugate | DLL3 | Phase 3 | Small Cell Lung Cancer (SCLC); Extrapulmonary Neuroendocrine Cancer (epNEC); Small Cell Lung Carcinoma (SCLC); Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 … | Mar 2027 |
| Nerandomilast formulation 1 Phosphodiesterase 4 (PDE4) inhibitor | PDE4 | Phase 3 | Interstitial Lung Diseases; Idiopathic Pulmonary Fibrosis; Fibrosing Interstitial Lung Disease; Familial Pulmonary Fibrosis … | Apr 2027 |
| Tenecteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 3 | Acute Ischemic Stroke | Oct 2027 |
| BI 764198 Sphingosine-1-phosphate receptor modulator | S1PR1 | Phase 3 | Focal Segmental Glomerulosclerosis; Proteinuric Kidney Diseases | Jan 2028 |
| BI 3000202 Type 1 interferon inhibitor | – | Phase 2 | Systemic Lupus Erythematosus; Healthy; Type 1 Interferonopathies | Dec 2026 |
| BI 3034701 | – | Phase 2 | Obesity; Healthy; Overweight | Dec 2026 |
| BI 764532 DLL3-targeting antibody-drug conjugate | DLL3 | Phase 2 | Small Cell Lung Carcinoma; Small Cell Lung Carcinoma (SCLC); Glioma; Neuroendocrine Neoplasms | Dec 2026 |
| BI 1584862 | – | Phase 2 | Geographic Atrophy | Dec 2026 |
| BI 764524 | – | Phase 2 | Diabetic Retinopathy | Mar 2027 |
| BI 765423 | – | Phase 2 | Idiopathic Pulmonary Fibrosis | Mar 2027 |
| BI 3032950 | – | Phase 2 | Ulcerative Colitis | Jul 2027 |
| BI 3802876 | – | Phase 2 | Liver Cirrhosis | Aug 2027 |
| BI 1815368 | – | Phase 2 | Macular Edema | Mar 2028 |
| Brigimadlin MDM2 inhibitor | MDM2 | Phase 2 | Solid Tumours | Dec 2030 |
| BI 771716 | – | Phase 2 | Macular Degeneration, Age-related | – |
| BI 765063 Immune checkpoint inhibitor antibody | – | Phase 1 | Carcinoma, Squamous Cell of Head and Neck (HNSCC) | Nov 2026 |
| BI 770371 Checkpoint inhibitor antibody | – | Phase 1 | Carcinoma, Squamous Cell of Head and Neck (HNSCC); Solid Tumors; Head and Neck Squamous Cell Carcinoma | Nov 2026 |
| Ezabenlimab PD-L2 inhibitor antibody | PDCD1LG2 | Phase 1 | Carcinoma, Squamous Cell of Head and Neck (HNSCC); Solid Tumors; Small Cell Lung Carcinoma (SCLC); Neoplasms … | Nov 2026 |
| BI 1701963 KRAS reactivation inhibitor | KRAS | Phase 1 | Solid Tumors, KRAS Mutation; Solid Tumors, KRAS Mutation; SOS1 | Nov 2026 |
| BI 1823911 KRAS inhibitor | KRAS | Phase 1 | Solid Tumors, KRAS Mutation | Nov 2026 |
| BI 3776528 | – | Phase 1 | Healthy | Feb 2027 |
| ATP150 Protein therapeutic (likely immunogenic protein) | – | Phase 1 | Pancreatic Ductal Adenocarcinoma | Mar 2027 |
| ATP152 Protein therapeutic (likely immunogenic protein) | – | Phase 1 | Pancreatic Ductal Adenocarcinoma | Mar 2027 |
| ATP162 Protein therapeutic (likely immunogenic protein) | – | Phase 1 | Pancreatic Ductal Adenocarcinoma | Mar 2027 |
| VSV-GP154 Oncolytic virus (vesicular stomatitis virus) | – | Phase 1 | Pancreatic Ductal Adenocarcinoma | Mar 2027 |
| BI 3812465 | – | Phase 1 | Diabetic Macular Edema | Mar 2027 |
| BI 3814916 | – | Phase 1 | Healthy | Jul 2027 |
| BI 3804379 | – | Phase 1 | Healthy | Feb 2028 |
| BI 765179 | – | Phase 1 | Neoplasms | Feb 2028 |
| BI 3819026 | – | Phase 1 | Advanced Solid Cancer | Jun 2028 |
| BI 1703880 Immune checkpoint modulator | – | Phase 1 | Solid Tumors | Sep 2028 |
| BI 3820768 immunotherapy (immune checkpoint modulator) | – | Phase 1 | Advanced Relapsed or Refractory Germ Cell Tumours | Sep 2029 |
| BI 3810944 | – | Phase 1 | Solid Tumours | Oct 2029 |
| BI 3822971 Immune checkpoint inhibitor | – | Phase 1 | Solid Tumours | Jan 2030 |
| BI 3968621 | – | Phase 1 | Advanced Solid Tumour | Sep 2030 |
| BI 3720931 (Lenticlair™-ON) Gene therapy for cystic fibrosis | CFTR | Phase 1 | Cystic Fibrosis | Oct 2040 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06683053 | Empagliflozin | Phase 3 | Congestive Heart Failure (CHF) | Cardiovascular | Apr 2024 |
| NCT06846411 | Empagliflozin | Phase 4 | Diabetes | Metabolic and endocrine | Sep 2025 |
| NCT06410352 | Empagliflozin | Phase 4 | Metabolic Syndrome | Metabolic and endocrine | Sep 2025 |
| NCT06342141 | Empagliflozin | Phase 2 | STEMI | Cardiovascular | Mar 2026 |
| NCT05510115 | Empagliflozin | Phase 2 | Polycystic Kidney, Autosomal Dominant | Genitourinary | Mar 2026 |
| NCT06933355 | Empagliflozin | Phase 4 | Kidney Transplantation Recipients | Metabolic and endocrine | Apr 2026 |
| NCT05687058 | Empagliflozin | Phase 1 | Kidney Failure, Chronic | Cardiovascular | May 2026 |
| NCT05553938 | Empagliflozin | Phase 1 | Heart Failure | Cardiovascular | May 2026 |
| NCT07214818 | Empagliflozin | Phase 2 | Nephrotic Syndrome | Genitourinary | Jul 2026 |
| NCT07586371 | Empagliflozin | Phase 2 | Proteinuria | Metabolic and endocrine | Jul 2026 |
| NCT07774325 | BI 3000202 | Phase 1 | Healthy | Other | Oct 2026 |
| NCT06722157 | BI 771716 | Phase 2 | Macular Degeneration, Age-related | Ophthalmology | Oct 2026 |
| NCT07708493 | BI 3034701 | Phase 1 | Healthy | Other | Oct 2026 |
| NCT05068102 | BI 765063 | Phase 1 | Carcinoma, Squamous Cell of Head and Neck (HNSCC) | Oncology | Nov 2026 |
| NCT05068102 | BI 770371 | Phase 1 | Carcinoma, Squamous Cell of Head and Neck (HNSCC) | Oncology | Nov 2026 |
| NCT05068102 | Ezabenlimab | Phase 1 | Carcinoma, Squamous Cell of Head and Neck (HNSCC) | Oncology | Nov 2026 |
| NCT04973163 | BI 1701963 | Phase 1 | Solid Tumors, KRAS Mutation | Oncology | Nov 2026 |
| NCT04973163 | BI 1823911 | Phase 1 | Solid Tumors, KRAS Mutation | Oncology | Nov 2026 |
| NCT05182658 | Empagliflozin | Phase 3 | Hypertrophic Cardiomyopathy | Cardiovascular | Nov 2026 |
| NCT06030843 | Empagliflozin | Phase 2 | Empagliflozin in Cardiorenal Syndrome Type 1 | Genitourinary | Nov 2026 |
| NCT06706791 | Empagliflozin | Phase 4 | Chronic Heart Failure | Cardiovascular | Dec 2026 |
| NCT05726032 | Empagliflozin | Phase 2 | Cirrhosis | Gastroenterology | Dec 2026 |
| NCT07692256 | Empagliflozin | Phase 2 | Heart Failure | Cardiovascular | Dec 2026 |
| NCT06878365 | BI 3000202 | Phase 1 | Type 1 Interferonopathies | Immunology | Dec 2026 |
| NCT07768813 | Survodutide | Phase 1 | Healthy | Metabolic and endocrine | Dec 2026 |
| NCT06151574 | Zongertinib | Phase 3 | Lung Cancer, Non-squamous, Non-small Cell | Oncology | Dec 2026 |
| NCT07845630 | Vicadrostat | Phase 1 | Healthy | Other | Dec 2026 |
| NCT07845630 | Empagliflozin | Phase 1 | Healthy | Other | Dec 2026 |
| NCT07845630 | Empagliflozin | Phase 1 | Healthy | Other | Dec 2026 |
| NCT07781631 | Verducatib (BI 1291583) | Phase 1 | Healthy | Other | Dec 2026 |
| NCT07789028 | Zongertinib | Phase 1 | Healthy | Other | Dec 2026 |
| NCT05963867 | BI 764532 | Phase 1 | Small Cell Lung Carcinoma (SCLC) | Oncology | Dec 2026 |
| NCT07837648 | BI 3034701 | Phase 1 | Healthy | Other | Dec 2026 |
| NCT05669742 | Empagliflozin | Phase 3 | Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics | Metabolic and endocrine | Dec 2026 |
| NCT06554301 | Empagliflozin | Phase 1 | Pulmonary Arterial Hypertension | Cardiovascular | Dec 2026 |
| NCT07760246 | Verducatib (BI 1291583) | Phase 1 | Healthy | Other | Dec 2026 |
| NCT07693231 | BI 3034701 | Phase 1 | Healthy | Metabolic and endocrine | Dec 2026 |
| NCT06769048 | BI 1584862 | Phase 2 | Geographic Atrophy | Ophthalmology | Dec 2026 |
| NCT07023354 | Verducatib (BI 1291583) | Phase 1 | Healthy | Gastroenterology | Dec 2026 |
| NCT07700940 | Empagliflozin | Phase 4 | Lupus Nephritis (LN) | Immunology | Dec 2026 |
| NCT05786443 | Empagliflozin | Phase 2 | End Stage Renal Disease | Genitourinary | Dec 2026 |
| NCT07336797 | Empagliflozin | Phase 2 | Metabolic Syndrome | Infectious disease | Dec 2026 |
| NCT07482020 | Empagliflozin | Phase 2 | Atrial Fibrillation (AF) | Cardiovascular | Dec 2026 |
| NCT06531824 | BI 690517 | Phase 3 | Kidney Disease, Chronic | Genitourinary | Dec 2026 |
| NCT05671991 | Empagliflozin | Phase 4 | End Stage Renal Disease on Dialysis | Genitourinary | Dec 2026 |
| NCT06055452 | Empagliflozin | Phase 4 | Pre-Heart Failure | Cardiovascular | Dec 2026 |
| NCT06989723 | Empagliflozin | Phase 4 | Type 2 Diabetes | Metabolic and endocrine | Dec 2026 |
| NCT06260059 | Empagliflozin | Phase 4 | Adult Congenital Heart Disease | Cardiovascular | Dec 2026 |
| NCT05392764 | Empagliflozin | Phase 3 | Acute Heart Failure | Cardiovascular | Dec 2026 |
| NCT06149793 | Empagliflozin | Phase 2 | Cystic Fibrosis-related Diabetes | Respiratory | Dec 2026 |
| NCT05202353 | Survodutide | Phase 1 | Obesity | Metabolic and endocrine | Jan 2027 |
| NCT06745284 | Survodutide | Phase 1 | Obesity | Metabolic and endocrine | Jan 2027 |
| NCT06894784 | Empagliflozin | Phase 3 | Diabetes Type 1 | Metabolic and endocrine | Jan 2027 |
| NCT07407348 | Survodutide | Phase 1 | Healthy | Metabolic and endocrine | Jan 2027 |
| NCT07372040 | Empagliflozin | Phase 2 | Acute Decompensated Heart Failure | Cardiovascular | Feb 2027 |
| NCT06745297 | BI 3776528 | Phase 1 | Healthy | Other | Feb 2027 |
| NCT07486102 | BI 3000202 | Phase 1 | Healthy | Gastroenterology | Feb 2027 |
| NCT06321302 | BI 764524 | Phase 2 | Diabetic Retinopathy | Ophthalmology | Mar 2027 |
| NCT05846516 | ATP150 | Phase 1 | Pancreatic Ductal Adenocarcinoma | Oncology | Mar 2027 |
| NCT05846516 | ATP152 | Phase 1 | Pancreatic Ductal Adenocarcinoma | Oncology | Mar 2027 |
The 60 nearest readouts of 173 trials; the rest in the app.
DLL3 (2) KRAS (2) GLP1R (1) GCGR (1) ERBB2 (1) S1PR1 (1) PDE4 (1) PDCD1LG2 (1) LYPLA1 (1) NR3C4 (1) SLC5A2 (1) PLAT (1)
Eli Lilly Roche Novartis Beijing Biotech Revolution Medicines Jiangsu HengRui Medicine Pfizer Novo Nordisk Amgen Chia Tai Tianqing Pharmaceutical Group
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.